Related references
Note: Only part of the references are listed.Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
Sonal Singh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2011)
Psychiatric Adverse Events Associated with Varenicline An Intensive Postmarketing Prospective Cohort Study in New Zealand
Mira Harrison-Woolrych et al.
DRUG SAFETY (2011)
Public health importance of triggers of myocardial infarction: a comparative risk assessment
Tim S. Nawrot et al.
LANCET (2011)
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease A Randomized Trial
Nancy A. Rigotti et al.
CIRCULATION (2010)
Varenicline in smoking cessation
Serena Tonstad et al.
Expert Review of Respiratory Medicine (2010)
Cigarette smoking: An undertreated risk factor for cardiovascular disease
Leif Erhardt
ATHEROSCLEROSIS (2009)
Systematic Assessment of Patients With Unexplained Cardiac Arrest Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER)
Andrew D. Krahn et al.
CIRCULATION (2009)
Purinergic signalling in autonomic control
Alexander V. Gourine et al.
TRENDS IN NEUROSCIENCES (2009)
Efficacy and safety of varenicline for smoking cessation
J. Taylor Hays et al.
AMERICAN JOURNAL OF MEDICINE (2008)
Cardiovascular effects of activation of central α7 and α4β2 nAChRs:: a role for vasopressin in anaesthetized rats
C. Moore et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Varenicline for Tobacco Dependence
J. Taylor Hays et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial
H-J Aubin et al.
THORAX (2008)
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Kathryn E. Williams et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
A randomized, placebo-controlled trial of varenicline, a selective alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
Shih-Tzu Tsai et al.
CLINICAL THERAPEUTICS (2007)
Smoking cessation efficacy and safety of varenicline, an α4β2 nicotinic receptor partial agonist
Serena Tonstad
JOURNAL OF CARDIOVASCULAR NURSING (2006)
Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors
Karla B. Mihalak et al.
MOLECULAR PHARMACOLOGY (2006)
Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist -: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up
Mitchell Nides et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation
Cheryl Oncken et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
The sympathetic control of blood pressure
PG Guyenet
NATURE REVIEWS NEUROSCIENCE (2006)
Hypertension, stroke, and endothelium
F Cosentino et al.
CURRENT HYPERTENSION REPORTS (2005)
ABC of smoking cessation - Bupropion and other non-nicotine pharmacotherapies
E Roddy
BRITISH MEDICAL JOURNAL (2004)
Clinical impact of selective spasm provocation tests: comparisons between acetylcholine and ergonovine in 1508 examinations
S Sueda et al.
CORONARY ARTERY DISEASE (2004)
Baroreceptor reflex pathways and neurotransmitters: 10 years on
PM Pilowsky et al.
JOURNAL OF HYPERTENSION (2002)
Adverse drug reactions: definitions, diagnosis, and management
IR Edwards et al.
LANCET (2000)
Central nicotinic receptors, neurotrophic factors and neuroprotection
N Belluardo et al.
BEHAVIOURAL BRAIN RESEARCH (2000)
Share Paper
